Head-to-head · WeighScore
MultiMedRx vs Sprout Health
By GLP-1 ScorecardUpdated
Score comparison
Sprout Health has the higher recorded score — 79.8/100 to 57.6/100.
Sprout Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Sprout advertises four-week compounded injection plans and separate annual prepayments; confirm the selected bill, pharmacy handoff and cancellation date.
Before you choose
MultiMedRx does not publish a semaglutide price, so its MultiMedRx review sets out what it does disclose, while the Sprout Health review explains the conditions attached to Sprout Health's figure. The semaglutide cost page compares published rates across the field. Ask MultiMedRx for a written total before treating either one as the cheaper choice.
If neither one fits, MultiMedRx vs Trimi and Nuform Health vs Sprout Health compare each of them with another graded program, and the list of alternatives to MultiMedRx ranks the programs closest to MultiMedRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | MultiMedRx | Sprout Health |
|---|---|---|
| WeighScore | 57.6/100 | 79.8/100 |
| Grade | C | C+ |
| Site position | #426 | #24 |
| Semaglutide | Not disclosed | $149/4 weeks (main-site offer; confirm selected plan) |
| Tirzepatide | Not disclosed | $199/4 weeks (main-site offer; confirm selected plan) |
| Coverage | Coverage not published | State exclusions in terms; confirm current eligibility |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Separates introductory and regular figures on the online cards.
- Describes evaluation and shipping in the advertised online package.
What to consider
- The public pages leave the selected debit, applicable care fee and renewal schedule unconfirmed.
- The published refund policy excludes sale items.
Site position #24 · C+
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Strengths
- Main-site compounded injection plans list $149 semaglutide / $199 tirzepatide per four weeks
- Evaluation, medication and shipping advertised as included
- Current policy allows a full refund before pharmacy transmission, including after clinical review
- Terms identify a clinical network and possible pharmacy contacts
What to consider
- The $99/$149 annual equivalents require $1,188/$1,788 upfront; selected offer terms need confirmation
- Four-week billing differs from calendar-month billing, and policy descriptions differ across plan types
- Cancellation requires 48-hour billing notice; shipment pauses need five business days
- Assigned clinician/pharmacy, state eligibility and current branded access remain unconfirmed
- An order becomes nonrefundable after pharmacy transmission; follow FDA guidance for warm injectable shipments
Featured provider
Sprout Health
Sprout Health scores 79.8/100 (C+). Sprout advertises four-week compounded injection plans and separate annual prepayments; confirm the selected bill, pharmacy handoff and cancellation date.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.